Thyroid Disorders Treatment
Thyroid Disorders Treatment
Thyroid treatment follows the axis the problem sits on. An underactive gland is given the hormone it is no longer making; an overactive gland is calmed by one of three approaches; and a structural finding in a gland that works normally is usually watched rather than treated. Almost every disappointment with thyroid treatment comes from expecting it to work on a timescale it does not work on. This page sets out what each option does, why the dose is re-measured weeks rather than days after a change, and what long-term care looks like.
Treatment follows the axis the problem sits on
Because thyroid disorders sit on two axes, treatment does too, and the first question is which axis the problem is on. An underactive gland needs the hormone it is no longer producing. An overactive gland needs its output reduced. A gland that looks different but works normally usually needs neither — it needs describing and, if a nodule is involved, assessing. Treating one axis in the hope of changing the other is the commonest way thyroid treatment goes wrong.
Two examples make the point. A person with normal blood tests and a small nodule is sometimes given thyroid hormone to "shrink" it, which does not work reliably and risks pushing a normal gland into overactivity. And a person who is tired with entirely normal thyroid function is sometimes started on hormone because the symptoms sound thyroidal, producing overactivity without addressing the real cause.
What treatment is aimed at also differs by direction. For an underactive gland the aim is to restore the hormone level to normal and hold it there, with TSH as the measure being adjusted against. For an overactive gland the aim is to bring output down and then to decide whether that reduction should be temporary or lasting — a decision that shapes which of the three categories below is discussed.
The sentence worth carrying away is that thyroid treatment is management of a hormone level rather than repair of a gland. That is not a consolation; it is the reason most people on the right dose feel entirely well and stay that way. What it does mean is that the plan has a schedule attached to it, and that schedule is set out in the section on the six-week rhythm below.
Levothyroxine — replacing what the gland no longer makes
Levothyroxine is thyroxine, the same hormone the gland makes, produced to a precise dose. The body converts part of it into the active form, triiodothyronine, which is why replacing T4 rather than T3 works: the body keeps its own control over how much is converted and where. Combination products containing T3 and preparations described as natural or desiccated thyroid are used in selected cases, but T4 alone is the standard, and it is the form whose monitoring is best established.
The starting dose is not one number for everyone. It depends on body weight, on how severe the deficiency is, on age, and above all on whether there is heart disease — because thyroid hormone increases the heart's work, and in someone with coronary disease or an arrhythmia the dose is started lower and raised more cautiously. In older people the same caution applies. That is why the first prescription is often deliberately modest and why the dose rises over the following weeks rather than being right immediately.
The target is a TSH inside the reference range, not a TSH at zero. Over-replacement is not a stronger version of the treatment: it produces the symptoms of an overactive gland, and sustained over-replacement carries risks to bone and to the heart rhythm, particularly after the menopause and in older people. The aim is normal, and the dose that achieves it is found rather than assumed.
The six-week rhythm: why a change is judged weeks later
This is the part of thyroid treatment that most affects ordinary life, and it is the part least often explained. When the dose changes, the new amount of hormone in the body does not settle immediately: it accumulates over several weeks before reaching a steady level. A change in dose is therefore judged about six weeks later, and a measurement taken before that describes the change rather than the result of it.
The consequences are practical. Measuring a week after a change gives a number that says "the dose has just gone up", and raising the dose again on the strength of it produces over-replacement — which is how people arrive with a suppressed TSH, a racing heart and a dose that is too high for them. Waiting is not caution for its own sake; it is the interval the measurement requires.
The same rhythm sets the review interval. While the dose is being found, appointments and blood tests are spaced about six weeks apart. Once the TSH is in range and has stayed there, the interval lengthens — commonly to once a year, with the same test and the same target. After any dose change, after starting or stopping a medicine known to interfere, after a pregnancy, and after a significant illness, the clock restarts and the interval tightens again.
This is also what makes care across borders workable. Because the adjustment is measured in weeks rather than days, most people do not stay in one place for a whole course of it. What has to travel with them is the target, the date of the next measurement, and the instruction about what would count as a reason to be checked sooner. How that is written down is set out on the living-with-it page.
What stops the tablet being absorbed
A correct dose that never gets absorbed is the same as a dose never taken, and it is one of the commonest reasons a person is described as needing far more thyroid hormone than expected. The tablet is absorbed in the upper small bowel, and a short list of things interferes with that.
| What interferes | What is done |
|---|---|
| Food, and coffee | Taken with water on an empty stomach, with an interval before the first meal as your team specifies; coffee is kept away from the dose rather than taken with it |
| Calcium and iron, including multiminerals | Bound in the gut. Separated from the dose by several hours, and the same for antacids containing aluminium or magnesium |
| Acid-reducing medicines, including proton pump inhibitors | Raising stomach pH reduces absorption. The dose is reviewed when one of these is started or stopped, rather than assumed unchanged |
| Conditions of the stomach and bowel | Coeliac disease, atrophic gastritis, Helicobacter infection, bariatric surgery and chronic diarrhoea each reduce absorption; treating the underlying condition is part of the answer |
| Soya, fibre and some supplements | Reduce absorption. Consistency matters more than avoidance: a routine that does not change is easier to dose against than one that does |
| Changing between brands or formulations | Different products are not always interchangeable at the same number. Where a change is unavoidable, the TSH is re-checked rather than assumed to be unchanged |
The practical rule is consistency rather than perfection. A person who takes the tablet at the same time, in the same way, with the same separations, every day, is easier to dose correctly than one whose routine changes weekly. Where a dose looks unexpectedly high, or where the TSH will not settle, absorption and timing are examined before the dose is raised again.
A missed dose is not an emergency. It is taken when it is remembered, and two doses are not taken together to make up for it; where several days have been missed, that is worth mentioning at the next review rather than compensating for.
Three categories of treatment for an overactive gland
An overactive gland is treated in one of three ways, and the choice between them is a decision made with the cause, the size of the gland, the severity, the age of the person, whether a pregnancy is planned, and whether the eyes are involved — not a matter of which is newest.
| Category | What it does, and what it requires |
|---|---|
| Antithyroid medicines | Reduce the amount of hormone the gland makes. Taken daily for a defined period, with blood tests to follow the thyroid and to watch for the uncommon effects on the blood count and the liver. They can bring about a remission, and they can also be used to stabilise before another option |
| Radioiodine | Taken once, concentrated by thyroid tissue and reduces the overactive cells from inside. Simple to give, and it commonly produces an underactive gland afterwards, which is then replaced with levothyroxine. Not used in pregnancy, and planned around pregnancy and around eye involvement |
| Surgery | Part or most of the gland is removed. Chosen where the gland is large, where there is a nodule that needs removing, where the eyes are involved, or where another option does not suit. It requires an operation and assessment beforehand, and the hormone level is followed afterwards |
What all three have in common is worth stating plainly, because it is the sentence people most often have to hear twice: each of them can end with an underactive gland requiring replacement. That is not a complication so much as the expected outcome of reducing output, and it is one reason the word "cure" fits this condition badly. What treatment achieves is a hormone level that is normal and stays normal, whether that is achieved with a tablet that replaces or with a course that ends in replacement.
Alongside all three, symptoms are often controlled in the first weeks with a beta-blocker, which slows the heart rate and settles the tremor while the underlying treatment takes effect. It treats the sensation rather than the cause, and it is not a substitute for whichever of the three is chosen.
The detail of how each is chosen, how long antithyroid treatment runs and what monitoring accompanies it belongs to the overactive thyroid guide, which is where this page hands over. Which category is appropriate for any individual, and whether one is available and suitable, is a clinical decision made with the full picture.
Normal function with a nodule — why hormone is not the answer
This combination is the commonest position on the grid, and it is the one most often treated unnecessarily. A nodule in a gland whose function is normal is a structural finding. Levothyroxine is not a treatment for it: giving hormone to suppress TSH does not reliably shrink nodules, and it does carry the risk of producing overactivity in a person who had none.
What a nodule does call for is characterisation by ultrasound and, where the size and appearance warrant it, sampling by fine-needle aspiration. Both are decided from the scan rather than from the blood tests, and both are described in the thyroid nodules guide. Where sampling establishes a diagnosis, that is followed in the thyroid cancer guide.
Where our endocrinology department is involved, thyroid nodule aspiration is performed to establish what a nodule is early rather than leaving it to be watched indefinitely. That is a diagnostic step on the structure axis, and it sits alongside — not instead of — the hormone assessment.
Living on long-term treatment
Most thyroid dysfunction is managed rather than cured, and the practical question is what the management consists of. In an underactive gland it is a tablet taken daily, a measurement of TSH at a stated interval, and a dose that changes occasionally. In an overactive gland it is a course of one of the three categories above, followed by the same rhythm of measurement, because the hormone level needs following for years rather than months in either direction.
What makes it work is mostly unglamorous: taking the tablet at the same time each day and in the same way; keeping the same brand where that is possible and having the TSH checked when it is not; mentioning every new medicine, supplement and antacid, because several of them change the dose needed; and attending the review even when everything feels fine.
What to stop doing: adjusting the dose by feel, stopping because a result was normal once, and starting a supplement containing iodine or kelp without saying so. What to keep: a written note of the dose, the brand, the last TSH with its date and reference range, and the target being worked towards.
Three situations deserve their own line. A pregnancy changes the requirement and the monitoring, and is covered on the living-with-it page. An illness severe enough to be admitted changes the results and the way the tablet is taken, and should be mentioned rather than managed alone. And a planned operation changes the instructions for the morning of surgery, which is worth settling in advance rather than on the day.
None of this is burdensome: a hormone level held in range and checked at a written-down interval is a condition being managed well.